Shares of Theratechnologies (TSX:TH) are down slightly today after the company reported its Q1, 2015 results.
In the quarter, the company lost $914,000 on revenue of $4.56-million, up 72% from Q4’s topline and a significant bump over last year’s Q1 revenue number of $1.67-million.
“As first-quarter results demonstrate, Theratechnologies is executing its business plan well,” said CEO Luc Tanguay. “Fundamentals are all going in the right direction, which brought us close to the break-even point in the first quarter. Growing sales in the United States combined with the approval of the one-milligram-per-vial presentation in Canada and the distribution agreement in Europe will add to our momentum in upcoming quarters.”
Theratech’s sales were from Egrifta, a treatment for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company purchased the rights for Egrifta back from distributor EMD Serono for $20 million, after several years of regulatory and manufacturing issues.
At press time, shares of Theratechnologies were down 2.4% to $1.22.
Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]
Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]
Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]
A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]
Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]
The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]